

=> d his

(FILE 'HOME' ENTERED AT 13:25:29 ON 05 MAR 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 13:25:46 ON 05 MAR 2003

L1	1	S	HYDROGEN PEROXIDE/CN
		E	BENZALKONIUM CHLORIDE/CN
L2	1	S	E3
		E	BENZETHONIUM CHLORIDE/CN
L3	1	S	E3
		E	IODINE/CN
L4	1	S	E3
		E	TRICLOSAN/CN
L5	1	S	E3
		E	NEOMYCIN/CN
L6	1	S	E3
		E	POLYMYXIN/CN
L7	3	S	E3, E4, E10
		E	BACITRACIN/CN
L8	1	S	E3
		E	CLINDAMYCIN/CN
L9	1	S	E3
		E	BENZOYL PEROXIDE/CN
L10	1	S	E3
		E	TETRACYCLIN/CN
L11	1	S	E5
		E	TETRACYCLIN
L12	670	S	E3, E4
		E	PENICILLIN/CN
L13	1	S	E3
		E	PENICILLIN
L14	2303	S	?PENICILLIN?/CNS
L15	1200	S	L14 NOT SQL/FA
L16	40381	S	NC3-NCSC2/ES
		E	99/RID
		E	99.81/RID
L17	39307	S	E3
L18	26778	S	L15-L17 AND 1/NC
L19	543	S	L12 NOT SQL/FA
L20	238	S	L19 AND C6-C6-C6-C6/ES AND 1/NC
L21	497	S	L18 AND L15
		E	QUINOLONE/CN
L22	1	S	E2
		E	RSD
L23	13403	S	591.300/RID AND NC5-NC5/ES AND 1/NC
L24	12411	S	L23 AND O>=1
		E	CEPHALOSPORIN/CN
L25	1	S	E3
		E	CEPHALOSPORIN
L26	407	S	E3
L27	115	S	L26 NOT SQL/FA
L28	93	S	L27 AND 1/NC
L29	77	S	L28 NOT ASE
L30	59	S	L29 NOT MAN/CI
L31	76652	S	NC3-NCSC3/ES
L32	76621	S	191.74/RID AND L31
L33	57441	S	L32 AND 1/NC
L34	50	S	L33 AND L26
L35	2	S	(ACYCLOVIR OR TAMIVIR OR PENCICLOVIR)/CN
		E	TAMIVIR
L36	12	S	(FARNESOL OR ECONAZOLE OR FLUCONASOLE OR CLOTRIMAZOLE OR KETO
		E	FLUCON/CN

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07-703-308-4498
jan.delaval@usoto.gov

L37 1 S E4
 E CICLOPIROX/CN
 L38 1 S E4
 E METRONIDAZOLE/CN
 L39 1 S E3
 L40 5 S (HYDROCORTISONE OR FLUCINOLONE ACETONIDE OR HALCINONIDE OR HA
 E FLUCINO/CN
 E HALOBETASOL/CN
 L41 1 S E4
 E CLOBETASOL/CN
 L42 1 S E7
 L43 6 S (ASPIRIN OR IBUPROFEN OR KETOPROFEN OR NAPROXEN OR ZINC OR AL
 L44 13246 S L2-L11,L13,L20,L21,L24,L25,L30,L34-L43
 L45 705 S 7722-84-1/CRN
 L46 0 S L44 AND L45
 L47 0 S L45 AND L12,L14-L21,L23,L24,L26-L33
 L48 13239 S L44 AND 1/NC

FILE 'HCAPLUS' ENTERED AT 13:43:45 ON 05 MAR 2003

L49 70013 S L1
 L50 162146 S H2O2 OR HYDROGEN PEROXIDE
 L51 163632 S L49,L50
 L52 4248 S L44 AND L51
 L53 3324 S L51 AND (ECHINAC? OR GOLDENSEAL OR GOLDEN SEAL OR BENZALKONIU
 L54 1071 S L51 AND (TRICLOSAN OR IRGASAN OR NEOMYCIN OR POLYMYXIN OR BAC
 L55 8 S L51 AND (ACYCLOVIR OR ACICLOVIR OR PENCICLOVIR OR PENCYCLOVIR
 L56 0 S TAMIVIR
 L57 0 S L51 AND ?AMIVIR?
 L58 81 S L51 AND (FARNESOL OR ECONAZOLE OR FLUCONAZOLE OR CLOTRIMAZOLE
 L59 1364 S L51 AND (SULCONAZOLE OR TERBINAFINE() (HCL OR HYDROCHLORIDE) O
 L60 202 S L51 AND (BETAMETHASONE DIPROPIONATE OR BETAMETHASONE VALERATE
 L61 8017 S L51 AND (WILLOWROOT OR WILLOW ROOT OR ZINC OR ZN OR ALLANTOIN
 L62 1820 S L51 AND (ANTIMICROB? OR ANTIBACTER? OR ANTIFUNG? OR ANTIVIR?
 E ANTIMICROB/CT
 E E6+ALL
 L63 2140 S L51 AND E4+NT
 E ANTIBACTERIAL/CT
 E E4+ALL
 L64 1416 S L51 AND E12-E14,E11+NT
 L65 109 S L51 AND E55-E57,E60,E82
 E ANTIVIRAL/CT
 E E5+ALL
 L66 196 S L51 AND E10,E11,E9+NT
 L67 10 S L51 AND E24
 E ANTHELMINTIC/CT
 E E6+ALL
 L68 53 S L51 AND E12+NT
 L69 16474 S L52-L68
 E INFLAMMATION/CT
 L70 244 S L51 AND E19,E24
 E E19+ALL
 E E2+ALL
 L71 228 S L51 AND E3+NT
 E NONSTEROID/CT
 E E5+ALL
 L72 26 S L51 AND E2
 E STEROID/CT
 L73 2145 S L51 AND E70+NT
 L74 444 S ANTI-INFLAMMATORY AGENTS/CT (L) STEROID?
 L75 3 S L51 AND L74
 L76 18414 S L69-L75
 L77 114 S L76 AND MOISTUR?
 L78 256 S L76 AND (SCALP? OR HAIR OR NAIL OR FINGERNAIL OR ?PSORIA? OR

```

      E PSORIASIS/CT
      E E3+ALL
L79    30 S L76 AND E4+NT
L80    34 S L76 AND E4,E5/BI
      E FOLLICULITIS/CT
      E FOLLIC/CT
      E E8+ALL
L81    1 S L76 AND E2
      E ROSACEA/CT
L82    0 S L76 AND E4
      E ACNE/CT
      E E6+ALL
L83    3 S L76 AND E2
      E NAIL/CT
      E E4+ALL
L84    9 S L76 AND E9,E10,E8+NT
      E DERMATITIS/CT
      E E3+ALL
L85    39 S L76 AND E6+NT
      E SEBORRH/CT
      E E4+ALL
L86    9 S L76 AND E5,E4+NT
      E DANDRUFF/CT
      E E3+ALL
L87    4 S L76 AND E4+NT
      E IMPETIGO/CT
      E E4+ALL
L88    4 S L76 AND E2
      E ANTIPSORIA/CT
      E ANTI-PSORIA/CT
      E ANTISEBOR/CT
      E ANTI-SEBOR/CT
      E ANTIDANDRUF/CT
      E E5+ALL
L89    0 S L76 AND E2
L90    257 S L78-L88
L91    8 S L90 AND L77
      E MURAD H/AU
L92    28 S E3,E4,E7
L93    4 S L92 AND L51
L94    9 S L91,L93
L95    24 S L92 NOT L94
      SEL DN AN 2 4 5 6 8 9 10 11
L96    8 S L95 AND E1-E22
L97    17 S L94,L96 AND L49-L96
      E HAIR/CT
      E E3+ALL
L98    22426 S E6,E5+NT
      E E15+ALL
L99    18078 S E2+NT
L100   129 S L76 AND L98,L99
L101    6 S L100 AND L77
L102   17 S L97,L101
L103    5 S L102 NOT L92
L104   12 S L102 NOT L103

```

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:17:43 ON 05 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Mar 2003 VOL 138 ISS 10
FILE LAST UPDATED: 4 Mar 2003 (20030304/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l104 all tot

L104 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2003 ACS
AN 2003:23346 HCAPLUS
DN 138:78489
TI Pharmaceutical compositions and methods for managing
dermatological conditions
IN **Murad, Howard**
PA USA
SO U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Pat. Appl. 2002
54,918.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K033-40
ICS A61K007-04; A61K007-06
NCL 424061000; 424070100; 424616000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 62
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003007939	A1	20030109	US 2002-77928	20020220
	US 6071541	A	20000606	US 1999-330127	19990611
	US 6296880	B1	20011002	US 2000-549202	20000413
	US 2002041901	A1	20020411	US 2001-878231	20010612
	US 6383523	B1	20020507		
	US 2002054918	A1	20020509	US 2001-953431	20010917
PRAI	US 1998-94775P	P	19980731		
	US 1999-330127	A2	19990611		
	US 2000-549202	A1	20000413		
	US 2001-878231	A2	20010612		
	US 2001-953431	A2	20010917		
AB	A pharmaceutical compn. for treating, preventing and managing conditions of skin, hair and nails , comprises (i) hydrogen peroxide for cleansing dermatol. surface without irritation, (ii) a moisturizing agent to facilitate hydration or prevent moisture loss, and (iii) one or more dermatol. agents selected from antimicrobial and anti-inflammatory agents are described. For example, a skin cleanser with antifungal and antibacterial agents was prepd. comprising (by wt.): Part A contg. water 50%, trisodium EDTA 0.2%, sodium laureth-13 Carboxylate 10%, disodium laureth sulfosuccinate 17%, disodium cocoamphodiacetate 11%, PEG-150 pentaerythrityl tetrastearate 1.5%, PEG-150 distearate 0.7%, and methylparaben 0.2%; Part B contg. clotrimazole 0.8%, citric acid 1.5%, and triclosan 0.3%;				

Part C contg. PPG-26-Buteth-26 and PEG-40 hydrogenated castor oil 2%, fragrance 0.3%, and menthol 0.1%; Part D contg. butylene glycol, water, and black cohosh ext. 0.1%, butylene glycol, water, Camellia oleifera ext. 0.1%, sodium peroxylinecarboxylic acid 0.2%, cocamidopropyl PG-dimonium chloride phosphate 1%; and Part E contg. 35 **hydrogen peroxide** 3%. Ingredients were mixed resulting in a colorless, clear, slightly viscous fluid having a pH at 25.degree. of 4-6 and a viscosity of 3000-4000 cps.

- ST **hydrogen peroxide antimicrobial**
antiinflammatory skin prepn; cosmetic topical **antimicrobial**
antiinflammatory **hydrogen peroxide**; hair
prepn **antimicrobial** antiinflammatory **hydrogen**
peroxide
- IT Quaternary ammonium compounds, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(alkylbenzyl dimethyl, chlorides; compns. contg. **hydrogen**
peroxide and **antimicrobial** and/or anti-inflammatory
agents for managing **dermatol.** conditions)
- IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aloe; compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing
dermatol. conditions)
- IT Surfactants
(amphoteric; compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing
dermatol. conditions)
- IT Hawthorn (Crataegus)
(berry exts.; compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing
dermatol. conditions)
- IT Cosmetics
(cleansing; compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing
dermatol. conditions)
- IT Acne
 Anthelmintics
 Antibacterial agents
 Antioxidants
 Antiviral agents
 Cosmetics
 Dandruff
 Dermatitis
 Hair preparations
 Immunostimulants
 Psoriasis
 Seborrhea
 Skin, disease
 Skin preparations (pharmaceutical)
 (compns. contg. **hydrogen peroxide** and
 antimicrobial and/or anti-inflammatory agents for managing
 dermatol. conditions)
- IT **Steroids, biological studies**
Sulfonamides
 Tetracyclines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing
dermatol. conditions)
- IT Human
(compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing

- dermatol. conditions in humans)
- IT **Scalp**
(disease; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT Acids, biological studies
Enzymes, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exfoliants; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Echinacea**
Golden seal (Hydrastis)
(exts., **antimicrobial**; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Arnica montana**
Black cohosh
Bupleurum
Ginger
Morinda citrifolia
Pomegranate
Poria cocos
Ranunculus ficaria
Rosemary
Rumex crispus
Soybean (Glycine max)
(exts.; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Hair**
(follicle, folliculitis; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Tea products**
(green, ext. of, green tea ext.; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Skin, disease**
(impetigo; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Nail (anatomical)**
(infection, fungal; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(licorice; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Cosmetics**
(lotions; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Perfumes**
(myrrh; compns. contg. **hydrogen peroxide** and **antimicrobial** and/or anti-inflammatory agents for managing dermatol. conditions)
- IT **Phenols, biological studies**
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(polyphenols, nonpolymeric, antimicrobial; compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT Antibiotics

(quinolone; compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT Gentian (Gentiana)

Marshmallow (Althaea officinalis)

Willow (Salix)

Yam (Dioscorea)

(root exts.; compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT Skin, disease

(rosacea; compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT Grape

(seed exts.; compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT Drug delivery systems

(topical; compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT 68-26-8, Retinol 69-72-7, Salicylic Acid, biological studies 79-14-1, Glycolic acid, biological studies 121-54-0, Benzethonium chloride 557-34-6, Zinc acetate 1314-13-2, Zinc Oxide, biological studies 3380-34-5, Triclosan 7553-56-2, Iodine, biological studies 7704-34-9, Sulfur, biological studies 7722-84-1, Hydrogen peroxide, biological studies 12001-79-5, Vitamin K 23593-75-1, Clotrimazole 68797-35-3, Dipotassium glycyrrhizate 106716-27-2, Amphosol CA
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)

(compns. contg. hydrogen peroxide and antimicrobial and/or anti-inflammatory agents for managing dermatol. conditions)

IT 50-23-7, Hydrocortisone 50-78-2,

Aspirin 67-73-2, Fluocinolone acetonide 76-25-5

, Triamcinolone acetonide 94-36-0, Benzoyl

peroxide, biological studies 97-59-6, Allantoin

112-38-9, Undecylenic acid 443-48-1,

Metronidazole 557-08-4, Zinc

undecylenate 1322-14-1, Calcium

undecylenate 1400-61-9, Nystatin

1404-04-2, Neomycin 1405-87-4,

Bacitracin 1406-05-9, Penicillin

1406-11-7, Polymyxin 2152-44-5,

Betamethasone valerate 3093-35-4,

Halcinonide 4602-84-0, Farnesol

5593-20-4, Betamethasone dipropionate

7440-66-6, Zinc, biological studies 11111-12-9

, Cephalosporin 15687-27-1, Ibuprofen

18323-44-9, Clindamycin 22071-15-4,

Ketoprofen 22204-53-1, Naproxen

22832-87-7, Miconazole nitrate

25122-46-7, Clobetasol propionate

27220-47-9, Econazole 41621-49-2,

Ciclopirox olamine 61318-90-9,
 Sulconazole 65277-42-1, Ketoconazole
 66852-54-8, Halobetasol propionate
 78628-80-5, Terbinafine hydrochloride
 86386-73-4, Fluconazole 101827-46-7,
 Butenafine hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. contg. **hydrogen peroxide** and
antimicrobial and/or anti-inflammatory agents for managing
dermatol. conditions)

IT 77-92-9, Citric acid, uses

RL: MOA (Modifier or additive use); USES (Uses)
 (**hydrogen peroxide** stabilizer; compns. contg.
hydrogen peroxide and **antimicrobial** and/or
 anti-inflammatory agents for managing **dermatol.** conditions)

IT 13721-01-2D, derivs., antibiotics

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**quinolone** antibiotics; compns. contg. **hydrogen**
peroxide and **antimicrobial** and/or anti-inflammatory
 agents for managing **dermatol.** conditions)

L104 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:695777 HCAPLUS

DN 137:237720

TI Organic acid and herbal drug compositions for treating dermatological disorders

IN Murad, Howard

PA USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-366

ICS A61K031-192; A61K035-78; A61K047-48; A61P017-00

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069963	A2	20020912	WO 2002-US6091	20020227
	WO 2002069963	A3	20021114		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002127256	A1	20020912	US 2002-80717	20020225
PRAI	US 2001-272046P	P	20010301		

AB The invention relates to dermatol. agents and methods for treating dermatol. disorders. The dermatol. agents include a therapeutically effective amt. of at least one acid selected from ellagic acid, ferulic acid, caffeic acid, or tannic acid in an amt. sufficient to strengthen cell membranes in the skin. The at least one acid is preferably combined with at least one of a moisturizing agent, an anti-inflammatory component, an immunity boosting component or an addnl. anti-oxidant, and a pharmaceutically acceptable carrier.

ST skin disorder compn org acid

IT Hawthorn (Crataegus)

(berry ext.; org. acid and herbal drug compns. for treating dermatol. disorders)

- IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(borage seed; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Amino acids, biological studies
RL: NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(hair keratin; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Tocopherols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(linoleate; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Perfumes
(myrrh; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Drug delivery systems
(oral; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Aloe barbadensis
Antimicrobial agents
Arnica
Black cohosh
Bupleurum
Chamomile
Gentian (Gentiana)
Ginger
Ginkgo biloba
Licorice (Glycyrrhiza)
Poria cocos
Ranunculus ficaria
Rosemary
Rumex crispus
Skin, disease
Soybean (Glycine max)
Yam (Dioscorea)
(org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Carboxylic acids, biological studies
Ceramides
Linseed oil
Natural products, pharmaceutical
Proteins
Steroids, biological studies
Tannins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primrose; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Willow (Salix)
(root, Canadian; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Marshmallow (Althaea officinalis robusta)
(root; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT Drug delivery systems
(topical; org. acid and herbal drug compns. for treating dermatol. disorders)
- IT 50-21-5, Lactic acid, biological studies 50-23-7, Hydrocortisone
50-81-7, Vitamin c, biological studies 56-81-5, Glycerol, biological studies
69-72-7, Salicylic acid, biological studies 77-92-9, Citric acid, biological studies
79-14-1, Glycolic acid, biological studies

97-59-6, Allantoin 117-39-5, Quercetin 331-39-5, Caffeic acid
 616-91-1, N-Acetylcysteine 1135-24-6, Ferulic acid 7439-96-5D,
 Manganese, compds. 7440-50-8D, Copper, compds. 7440-66-6, Zinc,
 biological studies 9004-61-9, Hyaluronic acid 9006-65-9, Dimethicone
 11103-57-4, Vitamin a 28874-51-3 65666-07-1, Silymarin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (org. acid and herbal drug compns. for treating dermatol. disorders)

L104 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:353986 HCAPLUS

DN 136:359653

TI Pharmaceutical compositions for managing skin conditions

IN **Murad, Howard**

PA USA

SO U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. 878,231.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K033-40

ICS A61K035-78

NCL 424616000

CC 63-6 (Pharmaceuticals)

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002054918	A1	20020509	US 2001-953431	20010917
	US 2002041901	A1	20020411	US 2001-878231	20010612
	US 6383523	B1	20020507		
	US 2003007939	A1	20030109	US 2002-77928	20020220
PRAI	US 2001-878231	A2	20010612		
	US 1998-94775P	P	19980731		
	US 1999-330127	A2	19990611		
	US 2000-549202	A1	20000413		
	US 2001-953431	A2	20010917		

AB This application relates to a pharmaceutical compn. and methods for treating inflammatory skin conditions. The compns. include **hydrogen peroxide**, 1 or more **moisturizing** agents, and an anti-inflammatory agent. The pharmaceutical compns. may optionally include 1 or more exfoliants. The compns. can be used to treat inflammatory skin conditions such as **dermatitis**, including, but not limited to **seborrheic dermatitis**, nummular **dermatitis**, contact **dermatitis**, atopic **dermatitis**, exfoliative **dermatitis**, and stasis **dermatitis**; **psoriasis**; **folliculitis**; **rosacea**; acne; **impetigo**; erysipelas; paronychia, erythrasma; and eczema. A skin cleanser formulation contained water 49.2, trisodium EDTA 10, Mackanate EL 17, Monateric CDX-38 11, Crothix 1.5, Kessco PEG-6000 DS 0.7, methylparaben 0.2, salicylic acid 1.6, citric acid 1.5, **Irgasan** DP-300 0.3, Solibilisant LR1 2, fragrance 0.3, menthol 0.1, butylene glycol 0.1, Snakeroot BG50 0.1, Ajidew-50 0.2, Phospholipid PTC 1, and 35% **H2O2** soln. 3%.

ST pharmaceutical **hydrogen peroxide** skin disorder

IT Surfactants

(amphoteric; pharmaceutical compns. for managing skin conditions)

IT **Dermatitis**

(atopic; pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(borage seed; pharmaceutical compns. for managing skin conditions)

IT Cosmetics

(cleansing; pharmaceutical compns. for managing skin conditions)

IT Skin, disease

(erysipelas; pharmaceutical compns. for managing skin conditions)

IT Skin, disease
(erythrasma; pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish, n-3 fatty acid-high; pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish, n-6 fatty acid-high; pharmaceutical compns. for managing skin conditions)

IT **Hair**
(**folliculitis**; pharmaceutical compns. for managing skin conditions)

IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; pharmaceutical compns. for managing skin conditions)

IT **Skin, disease**
(**impetigo**; pharmaceutical compns. for managing skin conditions)

IT Drug delivery systems
(lotions; pharmaceutical compns. for managing skin conditions)

IT Cosmetics
(**moisturizers**; pharmaceutical compns. for managing skin conditions)

IT Amino acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of keratin; pharmaceutical compns. for managing skin conditions)

IT Acne
Analgesics
Anesthetics
 Anti-inflammatory agents
 Antibacterial agents
Antioxidants
 Dermatitis
 Eczema
 Fungicides
Paronychia
Preservatives
 Psoriasis
 Seborrhea
Skin preparations (pharmaceutical)
Stabilizing agents
(pharmaceutical compns. for managing skin conditions)

IT Ceramides
Keratins
Linseed oil
Tannins
Tocopherols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primrose; pharmaceutical compns. for managing skin conditions)

IT **Skin, disease**
(**rosacea**; pharmaceutical compns. for managing skin conditions)

IT Drug delivery systems
(topical; pharmaceutical compns. for managing skin conditions)

IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wheat; pharmaceutical compns. for managing skin conditions)

IT **7722-84-1, Hydrogen peroxide**, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. for managing skin conditions)

IT 50-21-5, Lactic acid, biological studies **50-78-2**,
Aspirin 56-81-5, Glycerin, biological studies 60-33-3,
 Linoleic acid, biological studies 69-72-7, Salicylic acid, biological
 studies 77-92-9, Citric acid, biological studies 79-14-1, Glycolic
 acid, biological studies 81-13-0, Panthenol 9004-61-9, Hyaluronic acid
 9006-65-9, Dimethicone **15687-27-1**, **Ibuprofen**
22071-15-4, **Ketoprofen** **22204-53-1**,
Naproxen 28874-51-3 51744-92-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for managing skin conditions)

L104 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:719000 HCAPLUS

DN 135:262277

TI Pharmaceutical compositions and methods for managing skin conditions

IN **Murad, Howard**

PA USA

SO U.S., 18 pp., Cont.-in-part of U.S. 6,071,541.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K033-40

ICS A61K031-495; A61K031-35; A61K031-045

NCL 424616000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 62

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6296880	B1	20011002	US 2000-549202	20000413
	US 6071541	A	20000606	US 1999-330127	19990611
	US 2002041901	A1	20020411	US 2001-878231	20010612
	US 6383523	B1	20020507		
	US 2003007939	A1	20030109	US 2002-77928	20020220
	US 2002172719	A1	20021121	US 2002-93443	20020311
PRAI	US 1998-94775P	P	19980731		
	US 1999-330127	A2	19990611		
	US 2000-549202	A1	20000413		
	US 2001-878231	A2	20010612		
	US 2001-953431	A2	20010917		

AB This application relates to a stable pharmaceutical compn. and methods for the cleansing of skin to facilitate the prevention, treatment, and management of skin conditions, such as **seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo** and other inflammatory skin conditions, and the like, including a sufficient amt. of an acidic component of a hydroxyacid or tannic acid, or a pharmaceutically acceptable salt thereof, to exfoliate a portion of the skin, a sufficient amt. of stabilized **H2O2** to facilitate cleansing of the skin without substantial irritation thereof, and an **antimicrobial** agent including at least one of an **antibacterial** agent, **antimicrobial** agent, **antiviral** agent, **anthelmintic**, or a combination thereof, in an amt. sufficient to inhibit or reduce microorganisms on the skin.

ST skin disease treatment hydroxycarboxylate peroxide **antiviral**

IT Surfactants

(amphoteric; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)

IT Cosmetics

- (cleansing; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Drug delivery systems
(emulsions, topical; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Drug delivery systems
(gels, topical; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT **Skin, disease**
(**impetigo**; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Drug delivery systems
(lotions; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Drug delivery systems
(ointments, creams; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Drug delivery systems
(ointments; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT **Skin, disease**
(**pseudofolliculitis barbae**; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT **Skin, disease**
(**rosacea**; topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Acne
 Anthelmintics
 Anti-inflammatory agents
 Antibacterial agents
 Antioxidants
 Antiviral agents
 Dermatitis
 Fungicides
 Psoriasis
 Seborrhea
 (topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT Tannins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. for managing skin conditions contg. acids and **hydrogen peroxide** and **antivirals** and other actives)
- IT 50-21-5, Lactic acid, biological studies 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 557-34-6, Zinc acetate 1314-13-2, Zinc oxide, biological studies 3380-34-5, Triclosan 7704-34-9, Sulfur, biological

studies 7722-84-1, Hydrogen peroxide,
biological studies 23593-75-1, Clotrimazole
39809-25-1, Penciclovir 41621-49-2,
Ciclopilox olamine 59277-89-3,
Acyclovir 68797-35-3, Dipotassium glycyrrhizate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. for managing skin conditions contg. acids and
hydrogen peroxide and antivirals and other
actives)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Af Ekenstam; US 4557935 1985 HCAPLUS
- (2) Anon; GB 1135643 1968 HCAPLUS
- (3) Anon; GB 2076286 A 1981 HCAPLUS
- (4) Anon; CA 1174976 1984 HCAPLUS
- (5) Anon; EP 0191214 A2 1986 HCAPLUS
- (6) Anon; GB 2189294 B 1987
- (7) Anon; EP 2250539 B1 1991
- (8) Anon; EP 0425504 B1 1995 HCAPLUS
- (9) Bansemir; US 4900721 1990 HCAPLUS
- (10) Barton; US 5695745 1997 HCAPLUS
- (11) Bowing; US 4051058 1977 HCAPLUS
- (12) Bowing; US 4051059 1977 HCAPLUS
- (13) Burke; US 5296215 1994 HCAPLUS
- (14) Burke; US 5693318 1997
- (15) Claeys; US 4203765 1980
- (16) Cook; US 5008030 1991 HCAPLUS
- (17) Devillez; US 5958984 1999 HCAPLUS
- (18) Dresdner; US 5357636 1994
- (19) Ganci; US 4438102 1984 HCAPLUS
- (20) Hall; US 5547990 1996 HCAPLUS
- (21) Hopkins; US 4534945 1985 HCAPLUS
- (22) Jarrett; US 5593952 1997 HCAPLUS
- (23) Mills, O; Semin Dermatol 1982, P233
- (24) Newell; US 3297456 1967 HCAPLUS
- (25) Oliver; US 5869062 1999 HCAPLUS
- (26) Schmidt; US 5139788 1992 HCAPLUS
- (27) Scholz; US 5951993 1999 HCAPLUS
- (28) Sioufi; J of pharm Sciences 1977, V66/8, P1166
- (29) Yu; US 5641475 1997 HCAPLUS

L104 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:384405 HCAPLUS

DN 135:136841

TI The effect of an oral supplement containing glucosamine, amino acids,
minerals, and antioxidants on cutaneous aging: A preliminary study

AU Murad, H.; Tabibian, Michael P.

CS El Segundo, CA, USA

SO Journal of Dermatological Treatment (2001), 12(1), 47-51

CODEN: JDTREY; ISSN: 0954-6634

PB Martin Dunitz Ltd.

DT Journal

LA English

CC 18-7 (Animal Nutrition)

AB Alterations in collagen, elastin, and glycosaminoglycans contribute to
cutaneous changes seen in aging skin. A randomized, controlled,
single-blind study was conducted with 53 female volunteers who were
supplied with an oral supplement contg. glucosamine, amino acids,
minerals, and various antioxidant compds. Hydration properties of the
skin as well as textural anal. of the women's fine lines and wrinkles were
assessed following 5 wk intake of the oral supplement and results were
compared with those of a control group of 12 individuals who did not take
the supplement. There was a statistically significant redn. (34%) in the

no. of visible wrinkles as measured by the silflo replicas ($P < 0.01$) and a redn. (34%) in the no. of fine lines ($P < 0.06$) in the group of women who took the supplement. No significant changes in epidermal hydration were obsd. in either the control or study groups. The use of an oral supplement contg. glucosamine, minerals, and various antioxidant compds. can potentially improve the appearance of visible wrinkles and fine lines. It does not, however, affect epidermal hydration.

ST nutrition supplement glucosamine antioxidant skin aging; mineral amino acid supplement skin aging

IT Aging, animal

Antioxidants

Nutrition, animal

Skin

(effect of an oral supplement on cutaneous aging)

IT Amino acids, biological studies

Mineral elements, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(effect of an oral supplement on cutaneous aging)

IT Diet

(supplements; effect of an oral supplement on cutaneous aging)

IT 3416-24-8, glucosamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(effect of an oral supplement on cutaneous aging)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Asman, B; J Clin Periodontol 1994, V21, P45 MEDLINE
- (2) Cerimele, D; Br J Dermatol 1990, V122, P13
- (3) Costanzo, L; J Inorg Biochem 1995, V57, P115 HCAPLUS
- (4) Ditre, C; J Am Acad Dermatol 1996, V34, P187 MEDLINE
- (5) Fenske, N; J Am Acad Dermatol 1986, V15, P571 MEDLINE
- (6) Ghersetich, I; Int J Dermatol 1994, V33, P119 MEDLINE
- (7) Grange, R; Dermatology in general medicine 1993, P1451
- (8) Kligman, A; Dermatology in general medicine 1993, P2972
- (9) Kligman, L; Clin Geriatr Med 1989, V5, P235 MEDLINE
- (10) Masquelier, J; Parfums, cosmétiques et arômes 1990, V95, P89
- (11) Montagna, W; J Invest Dermatol 1979, V73, P47 MEDLINE
- (12) Oyama, Y; Brain Res 1994, V635, P125 HCAPLUS
- (13) Parat, M; Free Radic Res 1995, V23, P339 HCAPLUS
- (14) Plathak, M; Photochem Photobiol 1988, V47, P74S
- (15) Rongioletti, F; Dermatology 1995, V19, P19
- (16) Rosenbloom, J; Dermatol Foundation 1996, V30, P1
- (17) Sies, H; Am Rev Respir Dis 1987, V136, P478 HCAPLUS
- (18) Tanaka, H; Arch Dermatol Res 1993, V285, P352 HCAPLUS
- (19) Voorhees, J; J Int Med Res 1990, V18, P26

L104 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:152445 HCAPLUS

DN 134:212691

TI Pharmaceutical compositions containing sugars for reducing the appearance of cellulite

IN Murad, Howard

PA USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-00

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 62

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```

-----
PI WO 2001013865 A1 20010301 WO 2000-US22790 20000818
  W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
    HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
    LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
    SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
    ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
  RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
    DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
    CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1207840 A1 20020529 EP 2000-957590 20000818
  R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2003507400 T2 20030225 JP 2001-518005 20000818
US 2002137691 A1 20020926 US 2002-51189 20020122
PRAI US 1999-150034P P 19990820
US 2000-641376 A3 20000818
WO 2000-US22790 W 20000818
AB Compns. and methods for reducing or eliminating the appearance of
cellulite involves administering to a patient in need of treatment
therapeutically effective amts. of a sugar compd. that is converted to a
glycosaminoglycan in the patient in an amt. sufficient to thicken the
skin, a primary antioxidant component in an amt. sufficient to
substantially inhibit the formation of collagenase and elastase, at least
one amino acid component in an amt. sufficient to assist in the thickening
of the skin, and at least one transition metal component in an amt.
effective to bind collagen and elastic fibers and thicken skin so as to
reduce or eliminate the appearance of cellulite. A preferred method of
treatment further includes administering the components above in
conjunction with a vascular dilator to improve blood supply to the skin
and/or a fat burner to reduce absorption or digestion of fat in the
digestive tract or to prevent the prodn. of fat. The compns. and methods
may optionally include chromium picolinate to facilitate entry of sugar
into cells to improve fat metab. In one embodiment, these methods
encompass administering the amts. as a pharmaceutical compn.
ST cellulite redn pharmaceutical sugar
IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(binding of; pharmaceutical compns. contg. sugars for reducing the
appearance of cellulite)
IT Drug delivery systems
(capsules; pharmaceutical compns. contg. sugars for reducing the
appearance of cellulite)
IT Skin
(cellulite; pharmaceutical compns. contg. sugars for reducing the
appearance of cellulite)
IT Drug delivery systems
(oral; pharmaceutical compns. contg. sugars for reducing the appearance
of cellulite)
IT Ginkgo biloba
Ginseng (Panax)
Vasodilators
(pharmaceutical compns. contg. sugars for reducing the appearance of
cellulite)
IT Glycosaminoglycans, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pharmaceutical compns. contg. sugars for reducing the appearance of
cellulite)
IT Amino acids, biological studies
Carbohydrates, biological studies
Tannins
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);

```


THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

IT Antioxidants
 (pharmaceutical; pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

IT Drug delivery systems
 (tablets; pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

IT Drug delivery systems
 (topical; pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

IT 9001-12-1, Collagenase 9004-06-2, Elastase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

IT 50-81-7, Ascorbic acid, biological studies 56-87-1, L-Lysine, biological studies 63-91-2, L-Phenylalanine, biological studies 98-98-6D, Picolinic acid, complex with chromium 147-85-3, L-Proline, biological studies 616-91-1, N-Acetylcysteine 1398-61-4, Chitin 7440-47-3D, Chromium, complex with picolinic acid, biological studies 7512-17-6, N-Acetylglucosamine 9007-28-7, Chondroitin sulfate 27750-10-3, Hydroxycitric acid 29031-19-4, D-Glucosamine sulfate
 RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

IT 69-72-7, Salicylic acid, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. contg. sugars for reducing the appearance of cellulite)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
 (1) Bissett; US 6093411 A 2000 HCAPLUS
 (2) Bissett, D; US 5962482 A 1999 HCAPLUS
 (3) Cho; US 5529769 A 1996 HCAPLUS

L104 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:769191 HCAPLUS

TI Methods and compositions for treating dermatological disorders with fruitextracts

IN Murad, Howard

PA USA

SO PCT Int. Appl.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K039-385

ICS A61K007-00

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000064472	A1	20001102	WO 2000-US9625	20000410
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-130713P P 19990422
 US 2000-501217 A 20000210
 US 2000-501218 A 20000210

AB This application relates to methods and compositions for treating dermatological disorders. The method include administering a therapeutically effective amount of at least one fruit extract in an amount sufficient to neutralize free radicals, and a pharmaceutically acceptable carrier. The compositions include a therapeutically effective amount of at least one fruit extract in an amount sufficient to neutralize free radicals, a moisturizing agent in an amount sufficient to facilitate hydration of the skin, and a pharmaceutically acceptable carrier. Preferred fruit extracts include extracts from apricots, apples, peaches, pears, pineapples, papayas, pomegranates, cherries, kiwis, tangerines and oranges. The most preferred extract is extract from pomegranate.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Albeck; US 5124167 A 1992 HCAPLUS
- (2) Ishida; US 5141741 A 1992 HCAPLUS
- (3) Lansky; US 5891440 A 1999

L104 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:98301 HCAPLUS

DN 132:141692

TI Hair compositions containing hydroxy acids for managing scalp diseases

IN Murad, Howard

PA USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-07

ICS A61K031-19; A61K031-35; A61K031-44; A61K031-075

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006144	A1	20000210	WO 1999-US16866	19990726
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6207694	B1	20010327	US 1998-123484	19980727
AU 9952303	A1	20000221	AU 1999-52303	19990726
US 6271246	B1	20010807	US 1999-368078	19990803
US 2002009423	A1	20020124	US 2001-920729	20010803
US 6515007	B2	20030204		
PRAI US 1998-123484	A	19980727		
WO 1999-US16866	W	19990726		
US 1999-368078	A3	19990803		

AB This application relates to a compn. for the prevention, treatment, and management of scalp conditions, such as dandruff, seborrheic dermatitis, psoriasis, folliculitis, and hair thinning including a therapeutically effective amt. of an acidic component of a hydroxy acid or tannic acid, or a pharmaceutically acceptable salt thereof. A preferred anti-dandruff compn. and method of managing dandruff includes a therapeutically effective amt. of the acid component, a vitamin A component, and an anti-growth agent. A preferred anti-hair thinning compn. and method of managing thinning hair includes a therapeutically effective amt. of the

acidic component, a niacin component present in an amt. sufficient to locally increase blood circulation, and a 5- α . reductase inhibitor. The invention also relates to a method of treating chem. processed hair by administering to a patient an amt. of an acidic component of a hydroxy acid or tannic acid, or a pharmaceutically acceptable salt thereof, in an amt. sufficient to essentially close the cuticle and inhibit modification of the chem. processed hair. An anti-dandruff shampoo contained water 47, guar hydroxypropyltrimonium 0.1, glycolic acid 1.5, methylparaben 0.2, sodium laureth sulfate 28, glycol distearate 1, cocamidopropyl betaine 5, lauramide diethanolamine 2, salicylic acid 1.2, sodium laureth sulfate 10, allantoin 0.1, panthenol 0.3, dimethicone and laureth-4, and laureth-23 0.05, clotrimazole 0.5, denatured alc. 1.5, glycolic acid 0.15, phenoxyethanol 0.7, methylchloroisothiazolinone and methylisothiazolinone 0.05, retinyl palmitate 0.02, tocopherol 0.02, benzophenone-4 0.1, FE&C green no-3 0.02, ext. D&C violet no-2 0.2, and fragrance 0.3%.

- ST hair compn hydroxy acid scalp disease; antidandruff shampoo glycolic acid
- IT Shampoos
 - (antidandruff; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Hair preparations
 - (creams; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Scalp
 - (disease; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Hair preparations
 - (emulsions; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Hair preparations
 - (gels; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Anti-inflammatory agents
 - Antibacterial agents
 - Antioxidants
 - Circulation
 - Dandruff
 - Dyes
 - Fungicides
 - Preservatives
 - Psoriasis
 - Seborrhea
 - Stabilizing agents
 - (hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Tannins
 - RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 - (hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Carboxylic acids, biological studies
 - RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 - (hydroxy; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Yeast
 - (inhibitors; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Hair preparations
 - (lotions; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Cosmetics
 - (moisturizers; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Hair preparations
 - (sponges and ointments; hair compns. contg. hydroxy acids for managing scalp diseases)
- IT Hair preparations

(sprays; hair compns. contg. hydroxy acids for managing scalp diseases)
 IT 58-22-0, Testosterone 521-18-6, Dihydrotestosterone
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hair compns. contg. hydroxy acids for managing scalp diseases)
 IT 50-21-5, Lactic acid, biological studies 59-67-6, Niacin, biological
 studies 68-26-8, Vitamin a 69-72-7, Salicylic acid, biological studies
 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid,
 biological studies 614-18-6, Ethyl nicotinate 11103-57-4, Vitamin A
 23593-75-1, Clotrimazole 98319-26-7, Finasteride
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (hair compns. contg. hydroxy acids for managing scalp diseases)
 IT 9081-34-9, 5.alpha. Reductase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; hair compns. contg. hydroxy acids for managing scalp
 diseases)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Benelli, L; FR 2689008 A1 HCAPLUS
- (2) Brown, S; WO 6901632 A1 HCAPLUS
- (3) Dascalu, A; WO 9629045 A1 HCAPLUS
- (4) Duranton; WO 9302657 A1 HCAPLUS
- (5) Hamada, K; JP 09268115 A2 HCAPLUS
- (6) Hirota, O; JP 06234618 A2 HCAPLUS
- (7) Hourseau, C; FR 2666015 A1 1992 HCAPLUS
- (8) Kondo, T; US 4192863 1980 HCAPLUS
- (9) Saint-Leger, D; US 5650145 1997 HCAPLUS

L104 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:98263 HCAPLUS

DN 132:141966

TI Pharmaceutical compositions containing hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease

IN Murad, Howard

PA USA

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-48

ICS A61K033-40; A01N031-02; C11D003-48

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006116	A1	20000210	WO 1999-US17339	19990730
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6071541	A	20000606	US 1999-330127	19990611
AU 9952466	A1	20000221	AU 1999-52466	19990730
EP 1100454	A1	20010523	EP 1999-937680	19990730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1998-94775P	P	19980731		

US 1999-330127 A 19990611

WO 1999-US17339 W 19990730

- AB This application relates to a stable pharmaceutical compn. and methods for the cleansing of skin to facilitate the prevention, treatment, and management of skin conditions, such as **seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo** and other inflammatory skin conditions, and the like, including a sufficient amt. of an acidic component of a hydroxyacid or tannic acid, or a pharmaceutically acceptable salt thereof, to exfoliate a portion of the skin, a sufficient amt. of stabilized **hydrogen peroxide** to facilitate cleansing of the skin without substantial irritation thereof, and an **antimicrobial** agent in an amt. sufficient to inhibit or reduce microorganisms on the skin. A skin cleanser compn. contained water 49.2, EDTA 0.2, Surfine WLL 10, disodium laureth sulfosuccinate 17, disodium cocoamphodiacetate 11, PEG-150 pentaerythrityl tetrastearate 1.5, PEG-150 distearate 0.7, Me paraben 0.2, salicylic acid 1.6, citric acid 1.5, **triclosan** 0.3, Solubilisant LR1 2, fragrance 0.3, menthol 0.1, Actiphyte of black sankeroot BG50 0.1, sodium peroxylinecarboxylic acid 0.2, cocamidopropyl PG dimonium chloride phosphate 1, and 35% **hydrogen peroxide** 3%. Efficacy of the compn. in the treatment of acne is disclosed.
- ST pharmaceutical hydroxy acid **antimicrobial** skin disease;
hydrogen peroxide antimicrobial pharmaceutical skin disease
- IT Drug delivery systems
(emulsions; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Drug delivery systems
(gels; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Skin, disease
(**impetigo**; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Drug delivery systems
(lotions; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Cosmetics
(**moisturizers**; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Drug delivery systems
(ointments, creams; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Drug delivery systems
(ointments; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)
- IT Acne
Anti-inflammatory agents
Antibacterial agents
Antimicrobial agents
Antioxidants

Dermatitis

Dyes

Preservatives

Psoriasis**Seborrhea**

Skin, disease

Stabilizing agents

Surfactants

(pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)

IT Tannins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)

IT Drug delivery systems

(topical; pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)

IT 50-21-5, Lactic acid, biological studies 57-11-4, Stearic acid, biological studies 69-72-7, Salicylic acid, biological studies 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 3380-34-5, **Triclosan** 7722-84-1, **Hydrogen peroxide**, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. hydroxy acids, **hydrogen peroxide**, and **antimicrobial** agents for managing skin disease)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bansemir; US 4900721 A 1990 HCAPLUS
- (2) Burke; US 5296215 A 1994 HCAPLUS
- (3) Cook; US 5008030 A 1991 HCAPLUS
- (4) Hopkins; US 4534945 A 1985 HCAPLUS
- (5) Schmidt; US 5139788 A 1992 HCAPLUS
- (6) Sioufi; J Of Pharm Sciences 1977, V66(8), P1166 HCAPLUS
- (7) Yu; US 5641475 A 1997 HCAPLUS

L104 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:633299 HCAPLUS

DN 131:276962

TI Pharmaceutical compositions containing a zinc compound or vitamin A for treating acne

IN **Murad, Howard**

PA USA

SO U.S., 9 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-715

ICS A61K031-34; A61K031-19

NCL 514474000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5962517	A	19991005	US 1998-16800	19980130
PRAI	US 1997-36825P	P	19970131		

AB This invention relates to a pharmaceutical compn. for the treatment of acne having an acne redn. component, i.e. a Zn compd. or a vitamin A

source, in an amt. sufficient to reduce the redness and blemishes assocd. with acne. The invention also relates to pharmaceutical compns. having, in addn. to the acne redn. component, a skin cell conditioning component, e.g. a chromium compd., in an amt. sufficient to properly regulate the keratin and sebum prodn. of the skin cells, thereby inhibiting the appearance of acne. The compn. further includes at least one of a vitamin C source, burdock root, yellow dock root, horsetail ext., a catechin-based compn., a vitamin B1, B2, B3, B5, or vitamin E source. In a more preferred form, the invention also includes at least one amino acid component, a Mg or Se compd., and biotin. A tablet formulation was prepd. contg. vitamin E succinate, lysine, MgO, Zn ascorbate, Chromemate chromium GTF, vitamin A palmitate, Cr picolinate, vitamins, etc. The tablets were effective in reducing the incidence and severity of acne lesions with a mean decrease in the no. of lesions of 55%.

- ST vitamin A zinc oral topical acne
- IT Group VB element compounds
 - Group VIB element compounds
 - Group VIIB element compounds
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (N-contg.; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Drug delivery systems
 - (capsules; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Plant (Embryophyta)
 - (chaparral; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Equisetum
 - (ext.; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Elder (Sambucus)
 - (flowers; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Natural products, pharmaceutical
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (licorice; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Capsicum annuum annuum
 - (longum group; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Echinacea
 - Sassafras
 - Seaweed
 - (oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Alcohols, biological studies
 - Amino acids, biological studies
 - Carotenes, biological studies
 - Group IVB element compounds
 - Proanthocyanidins
 - Transition metal compounds
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Arctium lappa
 - Dandelion
 - Rumex crispus
 - (root; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Grape
 - (seed exts.; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)
- IT Drug delivery systems

(tablets; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)

IT Drug delivery systems
(topical; oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)

IT 50-81-7, L-Ascorbic acid, biological studies 56-87-1, L-Lysine, biological studies 58-56-0, Pyridoxine hydrochloride 58-85-5, Biotin 59-02-9 59-30-3, Folic acid, biological studies 59-43-8, Thiamine, biological studies 60-54-8, Tetracycline 62-49-7, Choline 79-81-2, Vitamin A palmitate 79-83-4, Pantothenic acid 83-88-5, Vitamin B2, biological studies 87-89-8, myo-Inositol 94-36-0, Benzoyl peroxide, biological studies 98-92-0, Niacinamide 114-07-8, Erythromycin 127-47-9, Vitamin A acetate 147-85-3, L-Proline, biological studies 150-13-0, p-Aminobenzoic acid 154-23-4, Catechin 302-79-4, Tretinoin 1309-48-4, Magnesium oxide, biological studies 1406-16-2, Vitamin D 3211-76-5, L-Selenomethionine 4345-03-3 4759-48-2, Isotretinoin 5743-27-1, Calcium ascorbate 7235-40-7, .beta.-Carotene 7439-95-4D, Magnesium, compds., biological studies 7440-09-7D, Potassium, compds., biological studies 7440-66-6D, Zinc, compds., biological studies 7440-70-2D, Calcium, compds., biological studies 7782-49-2D, Selenium, amino acid complexes, biological studies 8059-24-3, Vitamin B6 10098-89-2, L-Lysine hydrochloride 11103-57-4, Vitamin A 18323-44-9, Clindamycin 27882-76-4 74285-85-1 151728-40-4, Zinc ascorbate 245512-24-7, Chromemate Chromium GTF

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral and topical compns. contg. zinc, vitamin A, and skin conditioner for treating acne)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agarwal, R; Photochemistry and Photobiology 1993, V58(5), P695 HCAPLUS
- (2) Davis; Proc SPIE-Int Soc opt Eng 1996, V2679, P216 HCAPLUS
- (3) Deucher, G; Free Radicals and Aging 1992, V62, P428 MEDLINE
- (4) Elkhoury; US 5834480 1998 HCAPLUS
- (5) Hastings; US 5294606 1994 HCAPLUS
- (6) Hostetler; US 5654286 1997 HCAPLUS
- (7) Idson, B; Drug & Cosmetic Industry 1990
- (8) Macek, C; Medical News 1982, V247(13), P1800 MEDLINE
- (9) Maffei Facino, R; Arzneimittel-Forschung 1994, V44(1), P594
- (10) Matthews; US 5741212 1998
- (11) Mowry, D; The Scientific Validation of Herbal Medicine 1986, V248, P247
- (12) Mowry, D; The Scientific Validation of Herbal Medicine 1986, V248, P32
- (13) Murad; US 5804594 1998 HCAPLUS
- (14) Murray, F; Better Nutri f/Todays Living 1994, P52
- (15) Patrick; US 5496827 1996 HCAPLUS
- (16) Pizzorno, J; Natural Health 1996, P82
- (17) Poshi, P; J Amer Acad Derm 1991, V24(3), P1
- (18) Ramachandran; US 5834409 1998 HCAPLUS
- (19) Reinberg, A; Chronobiology International 1990, V7(1), P69 MEDLINE
- (20) Roche Laboratories Inc; Important Information Concerning Your Treatment with Accutane, 6th ed 1996
- (21) Swain, R; J Am Board Fam Pract 1995, V8, P206 MEDLINE
- (22) Tierra, M; Planetary Herbology P153
- (23) Tierra, M; Planetary Herbology P157
- (24) Trachtman, H; Biochemical and Biophysical Research Communications 1993, V191(2), P759 HCAPLUS
- (25) Whitaker, J; Dr Whitaker's Guide to Natural Healing 1995, P141
- (26) Whitaker, J; Dr Whitaker's guide to natural healing 1995
- (27) Xie, B; Proceedings of the National Science Council. Republic of China Part B, Life Sciences 1993, V17(2), P77 HCAPLUS
- (28) Zafirov, D; Acta Physiologica et Pharmacologica Bulgarica 1990, V16(3), P50 HCAPLUS

AN 1999:325772 HCAPLUS
 DN 130:343021
 TI Stable pharmaceutical compositions including ascorbic acid and methods of using same
 IN Murad, Howard
 PA USA
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-48
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924011	A1	19990520	WO 1998-US23529	19981104
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6194452	B1	20010227	US 1998-182180	19981030
	AU 9913072	A1	19990531	AU 1999-13072	19981104
PRAI	US 1997-64631P	P	19971107		
	US 1998-182180	A	19981030		
	WO 1998-US23529	W	19981104		
AB	The present invention relates to a non-irritating, stable pharmaceutical compn. including a soln. of at least one pharmaceutically acceptable silicone or oil and a source of pharmaceutically acceptable ascorbic acid, wherein the soln. is present in an amt. sufficient to inhibit degrdn. of the ascorbic acid while facilitating the prevention or treatment of skin damage. The present invention also relates to a method for modifying free radical damage to skin by administering the above pharmaceutical compn. in a therapeutically effective amt. sufficient to treat and/or prevent free radical damage to skin. A compn. was prepd. comprising Part A contg. octamethylcyclotetrasiloxane and organopolysiloxane 40 and tocopheryl acetate 10% by wt. and Part B contg. ascorbic acid 50%.				
ST	ascorbic acid stable pharmaceutical; siloxane ascorbic acid stable pharmaceutical				
IT	Polyoxyalkylenes, biological studies RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (di-Me, Me hydrogen polysiloxane-; stable ascorbic acid compns.)				
IT	Polysiloxanes, biological studies RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (di-Me, Me hydrogen, polyoxyalkylene-; stable ascorbic acid compns.)				
IT	Cyclosiloxanes RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (di-Me; stable ascorbic acid compns.)				
IT	Cosmetics (stable ascorbic acid compns.)				
IT	Carotenes, biological studies Polysiloxanes, biological studies RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (stable ascorbic acid compns.)				
IT	Drug delivery systems				

(topical; stable ascorbic acid compns.)
 IT 58-95-7, Tocopheryl acetate 68-19-9, Vitamin B12 79-81-2, Retinyl
 palmitate 7235-40-7, .beta.-Carotene 9006-65-9, Dimethicone
 11103-57-4, Vitamin A
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (stable ascorbic acid compns.)
 IT 50-81-7, Ascorbic acid, biological studies 556-67-2,
 Octamethylcyclotetrasiloxane
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses)
 (stable ascorbic acid compns.)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Tamabuchi; US 4818521 A 1989 HCAPLUS

L104 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:590741 HCAPLUS

DN 129:221193

TI Pharmaceutical compositions for improving wrinkles containing sugar
 compounds, antioxidants and amino acids

IN Murad, Howard

PA USA

SO U.S., 11 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-715

ICS A61K031-34; A61K031-19

NCL 514474000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5804594	A	19980908	US 1997-787358	19970122
	US 5972999	A	19991026	US 1998-146554	19980903
PRAI	US 1997-787358		19970122		

AB A pharmaceutical compn. for the prevention and treatment of skin
 conditions in a patient comprises a sugar compd. that is converted to a
 glycosaminoglycan in the patient in an amt. sufficient to thicken the
 skin, a primary antioxidant component in an amt. sufficient to
 substantially inhibit the formation of collagenase and elastase, at least
 one amino acid component in an amt. sufficient to assist in the thickening
 of the skin, and at least one transition metal component in an amt.
 effective to bind collagen and elastic fibers and rebuild skin. In one
 preferred form, the compn. further includes a catechin-based prepn., a
 glucosamine or a pharmaceutically acceptable salt or ester thereof, and a
 chondroitin or a pharmaceutically acceptable salt or ester thereof. In a
 more preferred form, the invention further includes a vitamin E source, a
 cysteine source, a vitamin B3 source, quercetin dihydrate, pyridoxal 5
 phosphate-Co B6, a methionine source, and a vitamin A source. The
 invention further relates to a method for the prevention or treatment of
 skin conditions by administering the pharmaceutical compn. in an amt.
 therapeutically effective to modify the thickness of the skin to prevent
 or treat at least one skin condition. A tablet contained
 N-acetylglucosamine 17.1, vitamin C 15, L-Lysine hydrochloride 12.2,
 L-proline 11, D-glucosamine sulfate 6.5, chondroitin sulfate 6.1, vitamin
 E succinate 4.3, zinc monomethionine 3.7, N-Acetyl cysteine 3.7, manganese
 ascorbate 2.8, vitamin B3 2.4, quercetin powder 2.4, grape seed ext. 0.9,
 proanthocyanidin pyridoxal 5 0.6, phosphate-co B6 0.6 selenoinethionine
 0.5, vitamin A palmitate 0.5, copper sebacate (14%) 0.4, red beet root
 powder 6.1, stearic acid 1.5, sorbitol 1.3, Acdisol 0.4, coconut oil 0.1

and Syloid 0.1 1 silicon% . Female subjects were administered 2 tablets/day for 5 wk. The no. of wrinkles and fine lines were reduced by 34%.

- ST pharmaceutical tablet wrinkle sugar antioxidant cosmetic; amino acid
pharmaceutical tablet wrinkle sugar
- IT Drug delivery systems
(capsules; pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT Carbohydrates, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds.; pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT Antioxidants
(pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT Amino acids, biological studies
Proanthocyanidins
Transition metals, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT Drug delivery systems
(tablets; pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT Cosmetics
(wrinkle-preventing; pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT 9001-12-1, Collagenase 9004-06-2, Elastase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)
- IT 50-81-7, Ascorbic acid, biological studies 50-81-7D, Ascorbic acid, salts and esters 52-90-4, Cysteine, biological studies 56-87-1, Lysine, biological studies 63-68-3, Methionine, biological studies 63-68-3D, Methionine, zinc complex 79-81-2, Vitamin a palmitate 79-83-4, Vitamin B3 98-92-0, Niacinamide 147-85-3, Proline, biological studies 1406-18-4, Vitamin E 3211-76-5, L-Selenomethionine 3416-24-8, Glucosamine 4345-03-3 6151-25-3, Quercetin dihydrate 7439-96-5D, Manganese, salts, biological studies 7440-50-8D, Copper, salts, biological studies 7440-66-6D, Zinc, methionine complex, biological studies 7440-66-6D, Zinc, salts, biological studies 7512-17-6, N-Acetylglucosamine 7512-17-6D, N-Acetylglucosamine, salts and esters 9007-27-6, Chondroitin 9007-28-7, Chondroitin sulfate 10098-89-2, Lysine hydrochloride 11103-57-4, Vitamin A 16351-10-3 32047-81-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for improving wrinkles contg. sugar compds., antioxidants and amino acids)

RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; GB 896940 1962 HCAPLUS
- (2) Anon; CA 1181693 1985 HCAPLUS
- (3) Anon; EP 0167363 A2 1986 HCAPLUS
- (4) Anon; CA 2066306 1992 HCAPLUS
- (5) Anon; JP 4029915 A 1992
- (6) Asman, B; J Clinical Periodontology 1994, V21(1), P45 MEDLINE
- (7) Band; US 5153174 1992 HCAPLUS

- (8) Bucci, L; Nutritional Supplement Advisor 1992
- (9) Carlozzi; US 3232836 1966
- (10) Cerimele, D; British Journal of Dermatology 1990, V122(Supplement 35), P13
- (11) Deucher, G; Antioxidant therapy in the aging process 1992, V62, P428
MEDLINE
- (12) Dioguardi; US 5198465 1993 HCAPLUS
- (13) Drovanti, A; Clinical Therapeutics 1980, V3(4), P1
- (14) D'Ambrosio, E; Pharmatherapeutica 1981, V2(8), P504 MEDLINE
- (15) Fenske, N; Journal of the American Academy of Dermatology, Part 1 1986,
V15(4), P571
- (16) Gimenez, A; Hepatology 1992, V16(3), P815 HCAPLUS
- (17) Goodman; US 5162303 1992 HCAPLUS
- (18) Grevenstein, J; Acta Orthopaedica Belgica 1991, V57(2), P157 MEDLINE
- (19) Henderson; US 5364845 1994 HCAPLUS
- (20) Henderson; US 5587363 1996 HCAPLUS
- (21) Hillebrand; US 5296500 1994 HCAPLUS
- (22) Kakoki; US 5415875 1995 HCAPLUS
- (23) Kuijer, R; Collagen and Related Research 1985, V5, P379 HCAPLUS
- (24) Le Fur; US 4956173 1990 HCAPLUS
- (25) Lubell, A; Cosmetic Dermatology 1996, V9(7), P58
- (26) Maffei, F; Arzneimittel-Forschung 1994, V44(5), P592
- (27) Meisner; US 4647453 1987 HCAPLUS
- (28) Mohammed; US 3773930 1973 HCAPLUS
- (29) Montagna, W; The Journal of Investigative Dermatology 1979, V73(1), P47
MEDLINE
- (30) Murray, M; Arthritis-A Natural Solution
- (31) Nachbar, F; J Molecular Medicine 1995, V73(1), P7 HCAPLUS
- (32) Neldner, K; Amer Acad Derm Annl Mtg 1993
- (33) Niebes; US 4285964 1981 HCAPLUS
- (34) Oyama, Y; Brain Research 1994, V635(1-2), P125 HCAPLUS
- (35) Parkinson; US 4424232 1984 HCAPLUS
- (36) Parkinson; US 4518614 1985 HCAPLUS
- (37) Parto, K; J Inherited Metabolic Disease 1993, V16(2), P441 MEDLINE
- (38) Pihlajaniemi, T; J Hepatology 1991, V13(Supp3), PS2
- (39) Rattan; US 5371089 1994 HCAPLUS
- (40) Reddy, G; Biochemical Pharmacology 1989, V38(20), P3527 HCAPLUS
- (41) Reiser, K; Faseb Journal 1992, V6(7), P2439 HCAPLUS
- (42) Rovati; US 3697652 1972 HCAPLUS
- (43) Sakurai; US 4716224 1987 HCAPLUS
- (44) Schinitzky; US 4938969 1990 HCAPLUS
- (45) Senin; US 4642340 1987 HCAPLUS
- (46) Setnikar, I; Armeim Forsch/Drug Res 1986, V36(1, 4), P729
- (47) Shan, Z; Kidney International 1994, V46(2), P388 HCAPLUS
- (48) Silvetti; US 4414202 1983 HCAPLUS
- (49) Soll; US 4486416 1984 HCAPLUS
- (50) Stoss, H; Veroffentlichungen aus der Pathologie 1990, V134, P1 MEDLINE
- (51) Sultenfuss; US 5281196 1994
- (52) Swain, R; J American Board of Family Practice 1995, V8(3), P206 MEDLINE
- (53) Tapadinhas, M; Pharmatherapeutica 1982, V3(3), P157 MEDLINE
- (54) Thomas, P; Medical World News 1991, P12
- (55) Todd, S; J Clinical Epidemiology 1995, V48(2), P307 MEDLINE
- (56) Umbdenstock; US 5308627 1994
- (57) Umbdenstock; US 5332579 1994
- (58) Werman, M; J Nutrition 1995, V125(4), P857 HCAPLUS
- (59) Xie, B; Life Sciences 1993, V17(2), P77 HCAPLUS
- (60) Zafirov, D; Acta Physiologica et Pharmacologica Bulgarica 1990, V16(3),
P50 HCAPLUS

=> d 1103 all tot

DN 136:107192
 TI Naphthomelanins, process for their preparation and compositions thereof
 IN Ghisalberti, Carlo
 PA Brazil
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-42
 ICS A61K007-48; C08G065-44
 CC 62-1 (Essential Oils and Cosmetics)
 Section cross-reference(s): 38

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002066	A1	20020110	WO 2000-IB1616	20001107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001011674	A5	20020114	AU 2001-11674	20001107
PRAI	IT 2000-MI1513	A	20000705		
	WO 2000-IB1616	W	20001107		

OS MARPAT 136:107192

AB The present invention relates to naphthomelanins obtainable by polymn. of polyhydroxynaphthalene monomers, alone or in combination or in conjunction with different dihydroxyarom. co-monomers. A process for the manuf. of naphthomelanins either by chem. or enzymic synthesis and the use of the naphthomelanins in cosmetic compns. useful to protect the skin, the mucous membranes and **hair** against UV-radiation and ageing, as well as to the use of the naphthomelanins as polymer additives useful for coloring and protecting against polymer degrdn. by UV-radiation and oxidn. are described. Thus, a dermoprotective foundation was prepd. contg. the naphthomelanin obtained by copolymn. of 1,6-dihydroxynaphthomelanin and lawsone in 4:1 molar ratio, resp. Also, when blended with polyvinylpyrrolidone and low-d. polyethylene into a film for a greenhouse roof, a naphthomelanin of the present invention provided a weather resistance of about 10-2.

ST naphthalene melanin cosmetic polymer stabilization prepn;

polyphenol polymn naphthomelanin cosmetic prepn

IT Skin, disease

(aging, protection against UV-radiation and aging; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)

IT Cosmetics

(antiaging; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)

IT Polymers, uses

RL: NUU (Other use, unclassified); POF (Polymer in formulation); PRP (Properties); USES (Uses)

(co-; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)

IT Anthocyanins

RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(copolymers with polyhydroxynaphthalenes; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)

IT **Hair preparations**

(dyes; prepn. of naphthomelanins for cosmetic uses and as polymer

- stabilizing additives)
- IT Polymerization
 - (enzymic; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT **Hair preparations**
 - (for protection against UV-radiation and ageing; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Cosmetics
 - (foundations; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Cosmetics
 - (makeups; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Cosmetics
 - (**moisturizers**; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Polymerization
 - (oxidative; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Brazilwood (Caesalpinia echinata)
 - Fustic (plant)
 - (**polyphenols**, copolymers with dihydroxynaphthomelanin; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Phenols, biological studies
 - RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (**polyphenols**, nonpolymeric, plant, copolymers with polyhydroxynaphthalenes; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Cosmetics
 - Oxidizing agents
 - Polymerization catalysts
 - Stabilizing agents
 - Sunscreens
 - Suntanning agents
 - (prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Enzymes, uses
 - RL: CAT (Catalyst use); USES (Uses)
 - (prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Polymers, uses
 - RL: NUU (Other use, unclassified); POF (Polymer in formulation); PRP (Properties); USES (Uses)
 - (prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Polymer blends
 - RL: NUU (Other use, unclassified); PRP (Properties); USES (Uses)
 - (prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Greenhouses
 - (prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives for greenhouse roof films)
- IT Metals, uses
 - RL: CAT (Catalyst use); USES (Uses)
 - (pro-oxidant; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Mucous membrane
 - (protection against UV-radiation and ageing; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT Polymer degradation
 - (protection against; prepn. of naphthomelanins for cosmetic uses and as

- polymer stabilizing additives)
- IT Polymer degradation
(weathering, protection against; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT 80498-15-3, Laccase
RL: CAT (Catalyst use); USES (Uses)
(Denilase II S; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT 9002-88-4, Polyethylene
RL: NUU (Other use, unclassified); POF (Polymer in formulation); PRP (Properties); USES (Uses)
(low-d.; prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT 7439-89-6, Iron, uses 7440-02-0, Nickel, uses 7440-48-4, Cobalt, uses 7440-50-8, Copper, uses 7758-98-7, Copper sulfate, uses 9002-10-2, Tyrosinase 9003-99-0, Peroxidase 9029-60-1, Lipoxxygenase
RL: CAT (Catalyst use); USES (Uses)
(prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT 575-44-0DP, 1,6-Naphthalenediol, copolymers with **polyphenols** of Brazil-wood 582-17-2DP, 2,7-Naphthalenediol, copolymers with anthocyanins 29254-61-3P 146291-51-2P 363151-82-0P 388081-62-7P 388081-63-8P 388081-64-9P 388081-65-0P 388081-66-1P 388081-67-2P 388081-68-3P 388081-69-4P 388081-70-7P
RL: COS (Cosmetic use); MOA (Modifier or additive use); NUU (Other use, unclassified); POF (Polymer in formulation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT 7722-64-7, Potassium permanganate 7722-84-1, **Hydrogen peroxide**, uses 7727-54-0, Ammonium persulfate 10034-81-8, Magnesium perchlorate 10034-85-2, Hydrogen iodide
RL: NUU (Other use, unclassified); USES (Uses)
(prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)
- IT 9003-39-8, Polyvinylpyrrolidone
RL: NUU (Other use, unclassified); POF (Polymer in formulation); PRP (Properties); USES (Uses)
(prepn. of naphthomelanins for cosmetic uses and as polymer stabilizing additives)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Herlihy, W; US 4515773 A 1985 HCAPLUS
- (2) Herlihy, W; US 4609544 A 1986 HCAPLUS
- (3) Ragimov, A; US 4396757 A 1983 HCAPLUS
- (4) Univ Yale; WO 9625920 A 1996 HCAPLUS

L103 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:300511 HCAPLUS

DN 134:315855

TI **Antimicrobial** compositions comprising pyroglutamic acid and metal salts

IN Biedermann, Kimberly Ann; Kronholm, Kurt Glen; Beerse, Peter William; Morgan, Jeffrey Michael; Mobley, Michael Joseph

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-195

ICS A01N037-46

CC 62-1 (Essential Oils and Cosmetics)

Section cross-reference(s): 10, 46, 63

FAN.CNT 24

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028552	A2	20010426	WO 2000-US28922	20001019
	WO 2001028552	A3	20010614		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000014778	A	20020716	BR 2000-14778	20001019
	EP 1225887	A2	20020731	EP 2000-970995	20001019
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-421131	A	19991019		
	WO 2000-US28922	W	20001019		
AB	The present invention relates to antimicrobial compns. which provide enhanced immediate as well as residual anti-viral and antibacterial efficacy. The antimicrobial compns. of the present invention provide previously unseen residual effectiveness against Gram neg. bacteria, Gram pos. bacteria, and viruses, fungi, and improved immediate germ redn. upon use. These compns. comprise: (a) a safe and effective amt. of pyroglutamic acid; (b) a safe and effective amt. of a metal salt; and (c) a dermatol. acceptable carrier for the acid and salt, wherein said compn. has a pH of 1-7. The invention further relates to methods of use for the present compns. as well as antimicrobial products which incorporate the compns. For example, a foaming facial, hand or body wash suitable for washing the skin is prepd. from the following ingredients using conventional mixing techniques: (A) sodium myristoyl sarcosinate 1.35%, disodium lauroamphoacetate 0.35%, sodium trideceth sulfate 0.35%, lauroamphoacetate 1.85%, PEG 120 Me glucose dioleate 2.7%, glycerin 2%; (B) dimethicone copolyol 1.3%, PEG 6 caprylic/capric glycerides 1%, phenoxyisopropanol 0.72%, Polyquaternium-10 0.5%, pyroglutamic acid 2.0%, Cuivridone 0.5%, CuCl2 0.1%, disodium EDTA 0.1%, glycol distearate 0.6%, sodium laureth sulfate 0.6%, cocamide MEA 0.12%, Laureth-10 0.12%, PEG 150 pentaerythritol tetrastearate 0.9%, fragrance 0.2%; and (C) water up to 100%, resp.				
ST	pyroglutamate salt topical antimicrobial cosmetic cleaning; disinfectant topical pyroglutamate salt cosmetic cleaning				
IT	Amine oxides RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C12-16-alkyldimethyl; antimicrobial compns. comprising pyroglutamic acid and metal salts)				
IT	Alcohols, biological studies RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C16-18, ethoxylated, cetareth; antimicrobial compns. comprising pyroglutamic acid and metal salts)				
IT	Glycerides, biological studies RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C8-10, ethoxylated; antimicrobial compns. comprising pyroglutamic acid and metal salts)				
IT	Sulfonic acids, biological studies RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

- (alkene, C14-16-; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyl dimethyl, chlorides; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT **Shampoos**
(**antidandruff**; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT **Antibacterial agents**
 Antimicrobial agents
 Antiviral agents
 Common cold
 Disinfectants
 Fungicides
 Gram-negative bacteria
 Gram-positive bacteria (Firmicutes)
 Mouthwashes
 Rhinovirus
 Scouring agents
 Surfactants
 (**antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Alcohols, biological studies
Amine oxides
Betaines
Carboxylic acids, biological studies
Polyoxyalkylenes, biological studies
Salts, biological studies
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Soaps
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Bath preparations
(body washes; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Essential oils
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clove; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Amides, biological studies
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco, N-(hydroxyethyl), cocamide MEA; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Respiratory tract
(disease; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Detergents
(dishwashing; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)
- IT Essential oils
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(eucalyptus; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Waxes
RL: NUU (Other use, unclassified); USES (Uses)
(floor; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Drugs
(gastrointestinal; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Bath preparations
Cosmetics
(gels; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Cosmetics
(hand sanitizers; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Cosmetics
(lotions; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Cosmetics
(moisturizers; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Drug delivery systems
(nasal sprays; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyether-; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Polyethers, biological studies
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(siloxane-; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Drug delivery systems
(solns., topical; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Essential oils
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thyme, *Thymus vulgaris*, thyme oil; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Paper
(tissue, facial; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT Medical goods
(wipes; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 15454-74-7, Cuivridone
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cuivridone; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 556-67-2, DC 344
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DC 344; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 128285-85-8, Dow Corning 580
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Dow Corning 580; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 2216-51-5, Levomenthol

RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Levomenthol; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 158050-37-4, Dow Corning Q 2-1401

RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Q 2-1401; **antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 50-70-4, Sorbitol, biological studies 57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological studies 57-55-6, Propylene Glycol, biological studies 58-95-7, Tocopheryl Acetate 64-02-8, Tetrasodium EDTA 64-17-5, Ethanol, biological studies 67-43-6, DTPA 67-63-0, Isopropanol, biological studies 69-72-7, Salicylic Acid, biological studies 79-10-7D, Acrylic acid, esters, polymers 81-13-0, Panthenol 88-04-0, p-Chloro-m-xylenol 90-43-7, o-Phenylphenol 98-79-3, Pyroglutamic acid 98-92-0, Niacinamide 102-71-6, Triethanolamine, biological studies 110-63-4, Butylene Glycol, biological studies 112-92-5, Stearyl Alcohol 118-55-8, Phenylsalicylate 122-99-6, Phenoxyethanol 139-44-6, Trihydroxystearin 142-91-6, Isopropyl palmitate 532-32-1, Sodium Benzoate 540-10-3, Cetyl palmitate 676-46-0, Sodium malate 770-35-4, Phenoxyisopropanol 994-36-5, Sodium Citrate 1191-50-0, Sodium myristyl sulfate 2235-54-3, Ammonium lauryl sulfate 2809-21-4, HEDP **3380-34-5, Triclosan** 5466-77-3, Parsol MCX 7149-65-7, L-Pyroglutamic acid ethyl ester 7439-89-6D, Iron, salts, biological studies 7440-02-0D, Nickel, salts, biological studies 7440-22-4D, Silver, salts, biological studies 7447-39-4, Copper(II) chloride, biological studies 7631-86-9, Silica, biological studies 7646-85-7, **Zinc** chloride (ZnCl₂), biological studies 7647-14-5, Sodium chloride, biological studies 7664-93-9D, Sulfuric acid, alkyl esters, biological studies 7705-08-0, Iron(III) chloride, biological studies **7722-84-1, Hydrogen peroxide**, biological studies 7758-98-7, Copper sulfate, biological studies 7761-88-8, Silver nitrate, biological studies 7772-99-8, Tin chloride (SnCl₂), biological studies 7786-81-4, Nickel(II) sulfate 9002-92-0, Laureth 10 9003-39-8, Luviskol K 17 9004-53-9, Dextrin 9004-64-2, Hydroxypropyl cellulose 9006-65-9, Dimethicone 9087-61-0, Aluminum Starch Octenyl Succinate 10028-22-5, Iron(III) sulfate 11138-66-2, Xanthan gum 13463-41-7, Pyrithione **zinc** 14350-97-1 15214-89-8 15435-29-7, Bromochlorophene 15827-60-8, DETPMP 18641-57-1, Syncrowax HRC 24937-16-4, Nylon-12 25038-74-8 25265-71-8, Dipropylene glycol 25301-02-4, Tyloxapol 25322-68-3, Polyethylene glycol 26027-38-3, Nonoxynol 14 30364-51-3, Sodium myristoyl sarcosinate 32612-48-9, Ammonium Laureth-3 Sulfate 36653-82-4, Cetyl Alcohol 39421-75-5, Jaguar HP 120 42233-14-7, Arachidyl Behenate 54116-08-4, Sodium trideceth sulfate 60908-77-2, Isohexadecane 67167-59-3, Polyethylene glycol stearate 81859-24-7, Polyquaternium 10 84861-79-0, Palmityl potassium phosphate 89382-86-5, Bentone EW 104365-77-7 125018-88-4, Glydant Plus 130249-48-8, Polyethylene glycol pentaerythritol tetrastearate 134499-37-9, Carbopol 954 138789-85-2, Pemulen TR1 156028-14-7, Sodium lauroamphoacetate 286384-03-0, Dow Corning QZ 3225C 335383-60-3, Aristoflex AVC
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 9003-05-8D, crosslinked 148093-12-3, Sepigel 305

RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antimicrobial** compns. comprising pyroglutamic acid and metal salts)

IT 13463-67-7, Titanium dioxide, biological studies

RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(silane-treated; **antimicrobial** compns. comprising
pyroglutamic acid and metal salts)

L103 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:790263 HCAPLUS

DN 133:339982

TI Biomimetic water solutions and compositions, their use as and in health
and beauty care products and the methods to prepare them

IN Colic, Miroslav

PA Henceforth Hibernia, Inc., USA

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-00

CC 62-4 (Essential Oils and Cosmetics)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066071	A1	20001109	WO 2000-US11615	20000428
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1176938	A1	20020206	EP 2000-928594	20000428
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	US 1999-131557P	P	19990429		
	WO 2000-US11615	W	20000428		
AB	The invention is directed to compns. of health and beauty care products which are produced by mimicking the human body's own defense mechanisms and the methods to produce and use such compns. The products are water based, oil and surfactant free and can be antimicrobicidal , without causing drying or itching of the skin. Moreover, such products enhance hydration and moisturizing of the skin and prevent itching. The products are based on water solns. of mixed oxidants, mimicking those produced by the human immune system cells. The invention also describes the processes for producing such products. Such products can be used independently, or to prep. creams, gels, lotions, tooth and other pastes, powders, suppositories, body and hair shampoos and rinses, oral and body hygiene rinses, creams and other products which would be obvious to those skilled in the art. A method of producing a biomimetic water soln. for health and beauty care comprises (a) electrochem. activating a soln. contg. purified water and sodium or potassium chloride to produce free chlorine and hypochlorite ions by electrolyzing said soln. in a device having a cathode compartment and an anode compartment; (b) collecting the activated soln. from said anode compartment; (c) introducing hydrogen peroxide into said collected soln.; (d) adjusting the pH of the soln. resulting from step (c) to about 5.5; and (e) removing said free chlorine from the soln. resulting from step (d).				
ST	biomimetic water soln health beauty care cosmetic; antimicrobial moisturizing biomimetic water soln; hypochlorite peroxide biomimetic water cosmetic				
IT	Aloe barbadensis Analgesics Anti-inflammatory agents				

Antibacterial agents**Antimicrobial agents**

Antitumor agents

Cosmetics

Dentifrices

Distillation

Drug delivery systems

Electrolysis

Health

Reverse osmosis

Shampoos

Solutions

Water purification

Wound healing

(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Oxidation

(biomimetic; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Cosmetics

(creams; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Skin, disease

(dry, reducing itching in; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT **Echinacea**

(ext.; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Cosmetics

(gels; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Electromagnetic field

Sound and Ultrasound

(in enhancing delivery; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Skin, disease

(insect bite, reducing itching in; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Drug delivery systems

(liposomes; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Cosmetics

(lotions; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Cosmetics

(moisturizers; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Drug delivery systems

(ointments; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Hygiene

(oral; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Antioxidants

(pharmaceutical; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Cosmetics

(powders; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Electric field

(pulsed, in enhancing delivery; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

IT Skin, disease

- (scar, treatment of; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT Drug delivery systems
(suppositories; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT Acne
Pruritus
(treatment of; biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT 69-72-7, Salicylic acid, biological studies 73-78-9, Lidocaine hydrochloride 616-91-1, N-Acetylcysteine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 60-00-4, EDTA, biological studies 9004-62-0, Hydroxyethylcellulose
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT 14380-61-1, Hypochlorite
RL: BUU (Biological use, unclassified); FMU (Formation, unclassified); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT 7681-52-9, Sodium hypochlorite **7722-84-1, Hydrogen peroxide**, biological studies 7732-18-5, Water, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT 7782-50-5, Chlorine, processes
RL: FMU (Formation, unclassified); REM (Removal or disposal); FORM (Formation, nonpreparative); PROC (Process)
(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)
- IT 7447-40-7, Potassium chloride, reactions 7647-14-5, Sodium chloride, reactions 10028-15-6, Ozone, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(biomimetic water solns. and compns. for health and beauty care products and methods to prep. them)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Biener, H; EP 0654270 A1 1995 HCAPLUS
- (2) Miz Co Ltd; JP 07277994 A 1995 HCAPLUS
- (3) Thorel, J; FR 2780887 A1 2000 HCAPLUS
- (4) Z P M Inc; WO 9824727 A1 1998 HCAPLUS

L103 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:465076 HCAPLUS

DN 127:86119

TI Cosmetic and **dermatological** compositions containing uric acid and uricase

IN Gohla, Sven; Wolf, Florian; Riedel, Jan-Henric

PA Beiersdorf A.-G., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German
 IC ICM A61K007-48
 ICS A61K007-40; A61K007-135; A61K007-021; A61K009-50; A61K031-52;
 A61K038-43

CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19547991	A1	19970626	DE 1995-19547991	19951221
	JP 09175991	A2	19970708	JP 1996-355471	19961224
PRAI	DE 1995-19547991		19951221		
AB	Topical compns. contg. sep. microencapsulated uric acid and uricase, when exposed to conditions which allow contact and reaction of these substances, generate <u>H2O2</u> and therefore exhibit antimicrobial and antiviral properties. Such compns. are useful in treatment of skin irritation, dermatitis, comedones, dermatomycosis, and superinfection of the skin with pathogens; they are also useful in deodorants, skin moisturizers, and hair bleaches. Thus, a water-in-oil lotion contained paraffin oil 25.00, silicone oil 2.00, ceresin 1.50, lanolin alc. 0.50, glucose sesquiossearate 2.50, uric acid 3.00, microencapsulated uricase 1.50, perfume, preservative, and water to 100.00 wt.% (pH 5.5-6.0).				
ST	urate uricase microbicide cosmetic dermatol; hydrogen peroxide generation cosmetic dermatol				
IT	Hair preparations (bleaches; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Hair preparations (conditioners; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Antimicrobial agents Cosmetics Detergents Microcapsules Shampoos Shaving preparations (cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Cosmetics (face packs; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Deodorants (gels, roll-on; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Cosmetics (lipsticks; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Drug delivery systems (microcapsules; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Cosmetics (moisturizers; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Drug delivery systems (ointments; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Cosmetics (skin-lightening; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	Drug delivery systems (topical; cosmetic and dermatol. compns. contg. uric acid and uricase)				
IT	69-93-2, Uric acid, biological studies 9002-12-4, Uricase				